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Background: This study describes and compares health-related quality of life (HRQOL) of prostate cancer patients
who received either radical prostatectomy (nerve-sparing, nsRP, or non-nerve-sparing, nnsRP) or radiotherapy
(external RT, brachytherapy, or both combined) for treatment of localised prostate cancer.
Methods: The prospective, multicenter cohort study included 529 patients. Questionnaires included the IIEF,
QLQ-C30, and PORPUS-P. Data were collected before (baseline), three, six, twelve, and twenty-four months after
treatment. Differences between groups’ baseline characteristics were assessed; changes over time were analysed
with generalised estimating equations (GEE). Missing values were treated with multiple imputation. Further,
scores at baseline and end of follow-up were compared to German reference data.
Results: The typical time trend was a decrease of average HRQOL three months after treatment followed by
(partial) recovery. RP patients experienced considerable impairment in sexual functioning. The covariate-adjusted
GEE identified a significant - but not clinically relevant - treatment effect for diarrhoea (b = 7.0 for RT, p = 0.006)
and PORPUS-P (b = 2.3 for nsRP, b = 2.2 for RT, p = 0.045) compared to the reference nnsRP. Most of the HRQOL
scores were comparable to German norm values.
Conclusions: Findings from previous research were reproduced in a specific setting of a patient cohort in the
German health care system. According to the principle of evidence-based medicine, this strengthens the messages
regarding treatment in prostate cancer and its impacts on patients’ health-related quality of life. After adjustment
for baseline HRQOL and other covariates, RT patients reported increased symptoms of diarrhoea, and nnsRP patients
decreased prostate-specific HRQOL. RP patients experienced considerable impairment in sexual functioning. These
differences should be taken into account by physicians when choosing the best therapy for a patient.
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Prostate cancer has a very long period of latency of up to
15–20 years during which the disease is histologically
present but has not yet become symptomatic. Autopsy
studies have shown that a relevant proportion of men – de-
pending on age and on ethnicity up to 83% (US whites, age
group 71–80 years) – has an occult prostate cancer [1,2].
Despite the conflicting evidence of benefits and harms
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unless otherwise stated.statutory health insurance in Germany, testing on pa-
tient request is common practice (approx. 30% per year
in men aged 45+) [5]. With the increasing use of PSA
testing it can be assumed that nowadays a relevant pro-
portion of former asymptomatic, occult cancer will be
diagnosed. Today, prostate cancer is the most common
malignancy in men in Germany with about 65,000 inci-
dent cases each year and a five-year prevalence of about
280,000 men [6].
As every screening test, including the PSA test, aims
to detect occult cancers at an early stage, one can as-
sume that a relevant proportion of screening detected
prostate cancers would not have become symptomaticral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sis. In these patients cancer treatment may have no
benefit but may result in treatment associated morbidity
[7]. As there is a moral imperative for treatment of can-
cer patients independent of tumour size, most young to
middle-aged patients with non-metastatic prostate can-
cer receive some kind of invasive treatment. The main
therapeutic strategies are radical prostatectomy (RP), ex-
ternal radiation, and interstitial brachytherapy. Each of
above therapies can achieve a five-year cancer-specific
survival of more than 90% [8]. Because of the favourable
prognosis of early stage tumours and because of treat-
ment morbidity, outcomes other than ‘survival’ are in-
creasingly important [9].
As a result, many studies focus on middle-term or
long-term health-related quality of life (HRQOL) out-
comes. For example, non-nerve-sparing RP (nnsRP) has
been shown to lead to a higher rate of incontinence and
impotence. Nerve-sparing RP (nsRP) has been reported
to have a positive impact on postoperative incontinence
and impotence [10,11], and is preferred whenever possible.
Examples of side effects of radiotherapy (RT) include irrit-
able urinary and bowel problems, i.e. symptoms that can
fundamentally compromise patients’ overall well-being
[12-14]. While it is desirable to detect early stages of pros-
tate cancer and thus lower mortality rates of prostate
cancer, these therapies can have substantial impact on the
HRQOL of cancer patients.
In view of the high proportion of overdiagnosis in
prostate cancer [15-17] and while there is ‘no optimal
way to treat localised prostate cancer’ [18], the pros and
cons of the available treatment options must be consid-
ered. The ProCaSP Study was an observational study
aimed at comparing longitudinal HRQOL outcomes
across a range of treatment groups for localised prostate
cancer in real-world treatment situations. In detail, it
was aimed at exploring inter-group differences between
two prostatectomy and three radiotherapy groups: 1)
nerve-sparing RP, 2) non-nerve-sparing RP, 3) brachy-
therapy (brachyRT), 4) external RT (externRT), and 5)
combined external and brachytherapy (combRT). In
addition, HRQOL of the cancer patients was compared
to a reference population.
Methods
The ProCaSP Study
The Prostate Cancer, Sexuality, and Partnership (Pro-
CaSP) Study was a German prospective multicenter
study. ProCaSP was aimed at evaluating HRQOL out-
comes of patients with localised prostate cancer treated
with either radical prostatectomy or radiotherapy. Fur-
thermore, the data included patients’ perceptions on
sexuality and partnership (data not reported) and their
partners’ HRQOL [19]. Inclusion criteria were stagesT1a to T3b according to the TNM-classification 5th
edition [20], no transurethral prostate resection within
the last six months, and prostate volume ≤50 ml. Ex-
clusion criteria were positive skeletal scintigraphy,
synchronic or metachronic secondary tumours, par-
ticipation in another study, and insufficient capacity to
contract. Patients were classified into different risk
groups [21].
The choice of treatment was based on a shared deci-
sion between patient and urologist. The decision regard-
ing nerve-sparing versus non-nerve-sparing procedure
was made by the hospital surgeon during surgery.Data collection
From 2002 to 2006, patients were recruited in ten German
study locations. Follow-up was completed in 2008.
Data were collected before (baseline), three, six, twelve,
and twenty-four months after the start of treatment.
Patients were asked to provide information on sociode-
mographic characteristics, treatment, sexual functioning,
and HRQOL.
Cancer-specific HRQOL, prostate-specific HRQOL, and
sexual functioning were measured by validated question-
naires (see below). Urinary functioning, which is of
interest as it is often compromised after RT, was mea-
sured by the best available instrument in German
language at that time, the Prostate Specific Module
(PSM) [22]. However, in our study cohort the PSM
was found to have insufficient psychometric properties
for some of the PSM scales and the data was, there-
fore, not considered in this analysis.European organisation of research and treatment in
cancer quality of life questionnaire, core module
(EORTC QLQ-C30)
The QLQ-C30 is a cancer-specific HRQOL measure.
Version 3.0 comprises 30 items covering five function-
ing scales, three symptom scales, six symptom items,
and two items on global HRQOL. Raw scores can be
transformed to a range between 0 and 100, with higher
functioning scores representing better functioning and
higher scores for symptoms/problems representing
worse conditions, respectively [23]. The minimal clin-
ically important difference (MCID) was set at ten
points [24].Patient-oriented prostate utility scale (PORPUS)
The PORPUS questionnaire is a prostate-specific HRQOL
instrument. The single HRQOL score, the PORPUS-P
[25,26], ranges from 0 to 100, with higher values repre-
senting higher HRQOL. Differences of five points were
interpreted as the MCID [25].
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The IIEF-15 measures sexual functioning. The 15 items
were summed up to a total score ranging between 5 and
75. Higher values correspond to higher functioning.
Ethics and consent
The study protocol was approved by the ethics commit-
tee of the Giessen University Hospital, Germany. All pa-
tients provided written informed consent.
Statistical analysis
Analyses were performed using R 3.0.2 [27]. First, pa-
tients’ sociodemographic characteristics and their tumor-
specific data were described with means (standard devia-
tions), absolute and relative frequencies. Differences in
patients’ characteristics between the three main groups
(nnsRP, nsRP, RT) were tested with Chi-square and F-
tests, respectively. Statistical significance was defined as
p< =0.05.
Second, time trends of mean HRQOL were presented
graphically by main treatment groups (nnsRP, nsRP, RT)
and by RT subgroups (brachyRT, externRT, and combRT).
Although we did not consider sexual functioning as a main
outcome, changes over time are shown to illustrate the dif-
ferent trends of the treatment group.
Third, the relationship between treatment (nnsRP,
nsRP, RT) and HRQOL was analysed using generalised
estimating equations (GEE) that account for the correlation
between repeated HRQOL observations. The HRQOL ob-
servations of the follow-up period were modeled depending
on respective treatment option, while adjusting for baseline
characteristics (baseline HRQOL, age, having a partner
(yes/no), highest education level (no graduation, 8–9 years
(‘Hauptschulabschluss’), 10–11 years (‘Realschulabschluss’),
>= 12 years high school (‘(Fach-)Abitur’), working (yes/no),
residence (rural/urban), tumour stage (T-category of the
TNM-classification), pre-therapeutic Gleason score, pre-
therapeutic PSA score, and sexual functioning at baseline
(IIEF total scale)). Regression coefficients of treatment op-
tions with their confidence intervals and Wald tests for
testing the effect of treatment option are reported. The ana-
lysis was repeated after splitting the RT group into the three
subgroups brachyRT, externRT, and combRT.
Most HRQOL domains and some patient characteris-
tics were affected by missing values ranging from 0% to
41.1%, with 22.7% of all observations missing. Multiple
imputation is known to be a statistically sound method
for handling incomplete data [28]. Hence, missing values
were imputed ten times depending on all patient charac-
teristics and on those observation times of HRQOL do-
mains with a correlation of at least 0.5. Results were
pooled according to Rubin’s Rule [28].
Fourth, the HRQOL scores at baseline and twenty-
four months after treatment of the three main treatmentgroups as well as the three RT subgroups were compared
to German norm values for the EORTC QLQ-C30 [29]
by calculating the reference score in a population with a
similar age distribution and presenting the difference be-
tween the treatment groups’ score and the reference
value.
Post hoc statistical power analysis
A post hoc power analysis was conducted using the soft-
ware package G*Power3 [30] with α = 0.05, two-tailed.
The calculation was based on a repeated measure
MANOVA for the two groups with the highest and the
lowest HRQOL, which had also the lowest sample sizes:
nsRP (n = 127) and RP (n = 133). The expected treatment
difference was the MCID, namely 10 for HRQOL and 5
for PORPUS-P. The standard deviation (SD) (between
10 and 20 for the different outcomes) and the correl-
ation between the four repeated measures of the individ-
uals (between 0.5 and 0.8) were estimated from the data.
Power was generally far above 95%.
Results
Patients and tumour characteristics
516 of the initial 529 patients had complete or partially
complete HRQOL data and were included. Approxi-
mately one of five observations for each HRQOL out-
come (23.9%) and one of the ten baseline covariate
values (13.3%) were missing for every patient. 256 pa-
tients received nnsRP, 127 nsRP, and 133 patients
received RT, of which 44 were treated by brachyRT, 52
by externRT, and 37 by combRT. More than half of
those patients treated with RT, where information on
pre-baseline androgen deprivation therapy was avail-
able, additionally received androgen deprivation ther-
apy (ADT) (52%).
Compared to patients receiving other treatment op-
tions, patients who underwent nsRP surgery were youn-
ger, were more often employed, more often living in a
rural area, and had a better baseline sexual functioning
(Table 1). Tumours that could not be treated nerve-
sparingly during surgery had more often an advanced
stage. RT patients were on average older than patients in
the other treatment groups, more often not employed,
living in urban areas, had a higher PSA level, more often
a small tumour stage, and a lower sexual functioning.
Comparison of D’Amico risk stratification revealed a
much lower risk for the RT treatment groups. More
than 80% of the nnsRP and nsRP patients were consid-
ered at high risk compared to less than 40% of the RT
patients (data after multiple imputation, not shown).
Pre-treatment PSA levels were highest in the combRT
group and lowest in the nsRP group, while Gleason
levels were highest in the nnsRP group and lowest in
the brachyRT group.
Table 1 Sociodemographic characteristics and tumor specific data
Radical prostatectomy Radiotherapy p-value1
Non-nerve-sparing
(reference)
Nerve-sparing Total Brachytherapy Combined (External/
brachytherapy)
External
(n = 256) (n = 127) (n = 133) (n = 44) (n = 37) (n = 52)
Age [mean ± SD] 64.2 ± 6.3 59.7 ± 6.1 66.5 ± 5.5 65.0 ± 6.0 66.8 ± 5.5 67.7 ± 4.8 <0.001
Partnership [N (%)]
Not living with a partner 14 (5.5) 6 (4.7) 10 (7.5) 4 (9.1) 3 (8.1) 3 (5.8) 0.586
Married or having a spouse 239 (93.4) 120(94.5) 121 (91.0) 39 (88.6) 33 (89.2) 49 (94.2)
Missing 3 (1.2) 1 (0.8) 2 (1.5) 1 (2.3) 1 (2.7) 0 (0.0)
Education [N (%)]
without - - 2 (1.5) 0 (0.0) 0 (0.0) 2 (3.8) 0.113
8-9 years 127 (49.6) 50 (39.4) 65 (48.9) 20 (45.5) 21 (56.8) 24 (46.2)
10-11 years 59 (23.0) 31 (24.4) 27 (20.3) 11 (25.0) 10 (27.0) 6 (11.5)
>=12 years 70 (27.3) 45 (35.4) 38 (28.6) 13 (29.5) 6 (16.2) 19 (36.5)
Missing - 1 (0.8) 1 (0.8) 0 (0.0) 0 (0.0) 1 (1.9)
Employment status [N (%)]
Employed 70 (27.3) 67 (52.8) 17 (12.8) 9 (20.5) 2 (5.4) 6 (11.5) <0.001
Non employed 180 (70.3) 59 (46.5) 114 (85.7) 33 (75.0) 35 (94.6) 46 (88.5)
Missing 6 (2.3) 1 (0.8) 2 (1.5) 2 (4.5) 0 (0.0) 0 (0.0)
Living area [N (%)]
Rural 149 (58.3) 85 (66.9) 56 (42.1) 29 (65.9) 18 (48.6) 9 (17.3) <0.001
Urban 102 (39.8) 40 (31.5) 71 (53.4) 12 (27.3) 17 (45.9) 42 (80.8)
Missing 5 (2.0) 2 (1.6) 6 (4.5) 3 (6.8) 2 (5.4) 1 (1.9)
Pre-therapeutic Gleason score,
[mean ± SD]
6.6 ± 1.2 6.5 ± 1.0 6.0 ± 13.1 5.4 ± 1.4 6.1 ± 1.6 6.4 ± 1.1 0.110
Missing [N] 2 1 33 25 7 3
Pre-therapeutic PSA score,
[mean ± SD]
11.4 ± 21.3 8.0 ± 4.7 13.7 ± 17.0 10.8 ± 15.0 17.6 ± 14.4 13.2 ± 19.9 0.032
Missing [N] 5 1 2 1 1 -
Pre-baseline androgen deprivation therapy [N (%)]
Yes 10 (3.9) 1 (0.8) 51 (38.3) 20 (45.4) 13 (35.1) 18 (34.6) <0.001
No 185 (72.2) 81 (63.8) 46 (34.6) 16 (36.4) 12 (32.4) 19 (36.5)
Missing 61 (23.8) 45 (35.4) 36 (27.0) 8 (18.2) 12 (32.4) 16 (30.8)
Tumour stage at diagnosis [N %)]
T1 2 (0.8) - 32 (24.0) 1 (2.3) 1 (2.7) 29 (55.8) <0.001
T2 142 (55.5) 103 (81.1) 39 (29.3) 8 (18.2) 17 (45.9) 14 (26.9)
T3 105 (41.0) 21 (16.5) 20 (15.0) 1 (2.3) 12 (32.4) 7 (13.5)
Missing 7 (2.7) 3 (2.4) 43 (32.3) 34 (77.3) 7 (18.9) 2 (3.8)
Risk stratification [N (%)]
Low 13 (5.1) 7 (5.5) 25 (18.8) 6 (13.6) 0 (0.0) 19 (36.5) <0.001
Intermediate 33 (12.9) 15 (11.8) 22 (16.5) 2 (4.5) 8 (21.6) 12 (23.1)
High 205 (80.1) 103 (81.1) 47 (35.3) 4 (9.1) 25 (67.6) 18 (34.6)
Missing 5 (1.9) 2 (1.6) 39 (29.3) 32 (72.7) 4 (10.8) 3 (5.8)
Operation condition [N (%)]
Retropubic 251 (98.0) 124 (97.6) n.a. n.a. n.a. n.a. n.a.
Perineal 5 (2.0) 2 (1.6)
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Table 1 Sociodemographic characteristics and tumor specific data (Continued)
Missing - 1 (0.8)
Sexual functioning, [mean ± SD] 41.5 ± 21.2 54.7 ± 16.5 33.1 ± 22.3 26.7 ± 22.1 32.4 ± 21.6 39.7 ± 21.7 <0.001
Missing [N] 92 36 44 11 15 18
1Chi-square and F- test for the three groups (non-nerve-sparing radical prostatectomy, nerve-sparing radical prostatectomy, and total radiotherapy), respectively.
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Figure 1 shows that the average sexual functioning of
the RT patients remains on a similar low level over the
whole observation period. Patients receiving nnsRP start
off with a higher sexual functioning, but end up with the
lowest scores. Patients receiving nnsRP have the highest
baseline scores, but drop by more than 20 points, ending
after a small recovery at a 24-month score similar to the
baseline score in RT patients. Additional file 1 presents
the trends for the three RT subgroups, which end with
very similar scores after 24 months of follow-up.
Generic HRQOL – QLQ-C30
Several of the baseline functioning or symptom scales
differed to a clinically relevant extent across the treat-
ment groups (physical, role, emotional, and social func-
tioning, fatigue, pain, dyspnoea, insomnia, and financial
difficulties). In all cases, the RT group – especially the
combRT group – had the least favourable baseline values
(Figure 2 and Additional file 2). The most favourable
value was generally found in the nsRP group, except for
emotional functioning, social functioning, and insomnia,
which was best in the externRT group. However, both
the nsRP and the nnsRP group most often showed
higher functioning and fewer symptoms than the total
RT group.Figure 1 Sexual functioning (IIEF). Mean scores of nnsRP, nsRP,
and RT cancer patients at baseline and during the 24-month follow-up
period after multiple imputation of missing values (solid line: nnsRP,
dashed line: nsRP, dotted line: RT).Three months after baseline, typically a decrease in
functioning scales and an increase in symptom scales were
seen, followed by a recovery (Figure 2 and Additional
file 2). Due to the smaller number of patients, the time
trends of the individual RT groups show a larger variability
and the typical time trend can be seen less clearly than in
the total RT group. When comparing nnsRP, nsRP, and the
total RT group, the following deviations from this pattern
were observed: In contrast to the more specific functioning
and symptom scales, the global health status was hardly af-
fected by treatment: It remained nearly unchanged for the
total RT group but further increased over time for the two
RP groups. The increase in emotional functioning was
clinically relevant in the nsRP group at six, twelve, and
twenty-four months and in the nnsRP group twelve
months after baseline. Physical functioning, role func-
tioning, and cognitive functioning worsened over time
for the RT group, a group of older patients compared
to those in the surgery groups. Among the RT groups,
the largest differences were observed for dyspnoea, in-
somnia, and financial difficulties.
In the multiple regression analysis, only diarrhoea
was statistically significantly associated with treatment
option after adjusting for baseline HRQOL, age, and
other demographical and clinical data (Table 2). RT
was estimated to increase the score on the diarrhoea
symptom scale by 7 points, while the estimate for
nsRP was −0.9. The RT effect was mostly driven by
the brachyRT group (effect of 7.8 compared to 4.1 and
4.2 for combRT and externRT). The difference was not
clinically relevant.Disease-specific quality of life – PORPUS-P
At baseline, the PORPUS-P score was highest in nsRP
and lowest in RT patients, in particular in patients
treated with combRT (Figure 3 and Additional file 3).
The difference was clinically relevant. The PORPUS-P
score decreased three months after baseline, followed by
a partial recovery.
In the covariate-adjusted multiple regression analysis a
statistically significant but not clinically relevant associ-
ation of main treatment option and HRQOL during the
follow-up period was observed (Table 2), with nsRP
patients having a significantly higher HRQOL and RT
patients also having a (not statistically significant) higher
HRQOL than nnsRP patients.
Figure 2 Health-related QoL (QLQ-C30). Mean scores of nnsRP, nsRP, and RT cancer patients at baseline and during the 24-month follow-up
period after multiple imputation of missing values (solid line: nnsRP, dashed line: nsRP, dotted line: RT).
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Overall, scores of the treatment groups at baseline and
twenty-four months after treatment were mostly com-
parable to German norm values for the EORTC QLQ-
C30 [29] (Table 3). However, patients treated with RP
had clinically relevant lower scores of fatigue and pain at
baseline, and the low pain score persisted for the nsRP
patients for twenty-four months. The nsPR patients had
a clinically relevant higher role functioning than ex-
pected at baseline and at the end of the follow-up. No
clinically relevant deviations from the norm values wereobserved for the total group of patients treated with RT.
However, the brachyRT group had a clinically relevant
higher role functioning at baseline than expected. The
externRT group had a higher role functioning at baseline
as well, and lower symptoms of pain, which slightly de-
creased to a clinically non-relevant level until twenty-
four months later. The combRT group had clinically
relevant lower emotional and social functioning and
higher insomnia scores at baseline, and less pain but
more insomnia than the reference population twenty-
four months after baseline.
Table 2 Estimated effect of treatment option on HRQOL in a multiple regression analysis




Radiotherapy Wald test Radiotherapy Wald test




b b 95%-CI b 95%-CI p-value b 95%-CI b 95%-CI b 95%-CI p-value
QLQ-C30
Functioning scales
Global health status 0 2.9 (−0.6, 6.4) −2.0 (−5.9, 2.0) 0.098 −1.0 (−6.2, 4.2) −2.2 (−8.4, 3.9) −4.4 (−9.9, 1.2) 0.120
Physical functioning 0 1.7 (−0.6, 4.1) −0.9 (−4.3, 2.4) 0.198 −0.6 (−5.4, 4.3) −0.6 (−5.2, 3.9) −3.5 (−8.9, 2.0) 0.224
Role functioning 0 1.9 (−1.5, 5.3) −0.5 (−4.8, 3.8) 0.425 −1.6 (−7.9, 4.7) 2.0 (−4.7, 8.7) −2.5 (−8.8, 3.8) 0.314
Emotional functioning 0 3.8 (−0.2, 7.8) −2.7 (−7.3, 2.0) 0.074 −2.4 (−8.7, 3.9) 1.1 (−6.2, 8.3) −8.6 (−15.2, −2.0) 0.028
Cognitive functioning 0 2.5 (−1.1, 6.2) −1.8 (−5.5, 1.9) 0.170 −0.7 (−6.0, 4.5) −2.2 (−8.2, 3.8) −2.7 (−9.5, 4.0) 0.277
Social functioning 0 1.2 (−3.7, 6.1) 0.1 (−5.4, 5.5) 0.650 −0.7 (−7.9, 6.5) 3.0 (−5.1, 11.1) −5.7 (−14.3, 3.0) 0.287
Symptom scales
Fatigue 0 −3.6 (−7.8, 0.5) 0.4 (−4.6, 5.3) 0.173 0.1 (−6.6, 6.8) −1.6 (−9.1, 5.9) 5.4 (−2.0, 12.9) 0.174
Nausea and vomiting 0 −0.5 (−1.6, 0.6) 1.1 (−0.5, 2.7) 0.100 2.1 (0.1, 4.1) −0.5 (−2.2, 1.2) 0.6 (−1.8, 2.9) 0.091
Pain 0 0.5 (−3.5, 4.5) 2.7 (−2.2, 7.5) 0.477 3.6 (−3.3, 10.5) 0.1 (−7.2, 7.3) 3.4 (−4.8, 11.6) 0.601
Dyspnoea 0 1.4 (−2.1, 4.8) 3.5 (−0.8, 7.8) 0.177 0.1 (−5.6, 5.8) 6.8 (−0.5, 14.1) 4.8 (−1.5, 11.0 0.122
Insomnia 0 0.1 (−4.7, 5.0) 3.2 (−2.5, 8.9) 0.451 4.3 (−2.9, 11.5) 4.0 (−4.7, 12.7) 6.4 (−2.8, 15.6) 0.291
Appetite loss 0 −0.1 (−2.3, 2.1) 1.5 (−1.7, 4.7) 0.317 1.5 (−1.8, 4.8) 1.0 (−3.7, 5.6) 3.1 (−1.5, 7.6) 0.276
Constipation 0 −1.2 (−5.3, 3.0) 0.4 (−4.1, 4.9) 0.542 1.7 (−4.2, 7.5) −0.9 (−8.4, 6.5) 3.2 (−5.5, 12.0) 0.362
Diarrhoea 0 −0.9 (−4.4, 2.6) 7.0 (2.5, 11.6) 0.006 7.8 (1.0, 14.5) 4.1 (−3.3, 11.4) 4.2 (−3.6, 12.0) 0.048
Financial difficulties 0 −3.1 (−7.0, 0.8) −0.2 (−4.7, 4.3) 0.257 −2.7 (−9.1, 3.7) −0.5 (−8.8, 7.7) 4.9 (−4.0, 13.8) 0.216
PORPUS
PORPUS-P 0 2.3 (0.1, 4.6) 2.2 (−0.6, 5.0) 0.045 2.2 (−1.6, 6.1) 3.3 (−0.6, 7.2) 1.4 (−3.0, 5.7) 0.119
Ref = Non-nerve-sparing radical prostatectomy as reference level.
Bold values indicate significance at the 5%-level.
1As the regression coefficients of the radical prostatectomy group did not change much, only the regression coefficients of the radiotherapy subgroups with their
confidence intervals and the Wald test p-values are reported.
Both analyses are adjusted for baseline HRQOL, age, having a partner (yes/no), highest education level (no graduation, 8–9 years (‘Hauptschulabschluss’), 10–11
years (‘Realschulabschluss’), >= 12 years high school (‘(Fach-)Abitur’)), working (yes/no), residence (rural/urban), tumour stage (T-category of the TNM-classification),
pre-therapeutic Gleason score, pre-therapeutic PSA score, and sexual functioning at baseline (IIEF total scale).
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The complete case analysis was based on 248 to 254
patients, depending on the HRQOL measure. Results
were mostly similar to the results after multiple imput-
ation presented above. Global health status, emotional
functioning, and appetite loss, but not diarrhoea, were
additionally found to be significantly (but not clinically
relevantly) related to main treatment option.Discussion
This study analysed changes of HRQOL of prostate
cancer patients over time, the effect of treatment on
HRQOL, and compared HRQOL to that in a German
reference population.Changes over time
The descriptive comparison of time trends showed that
a decreased sexual functioning and limited recovery is
more common in RP than in RT. Although the compari-
son does not convey information about a treatment ef-
fect on similar/randomised groups, it describes what
happens to men with prostate cancer in actual health
care. The finding is in concordance with other publica-
tions [31,32]. Further, better outcomes in erectile func-
tioning for nsRP patients compared to patients with
non-nerve-sparing procedures were also found in previ-
ous studies [10,11,33]. Still, erectile functioning is a con-
cern in RP in general [34-36].
In view of generic HRQOL, only minor changes over
time were seen across groups. In several other studies
Figure 3 PORPUS-P. Mean scores of nnsRP, nsRP, and RT cancer
patients at baseline and during the 24-month follow-up period
after multiple imputation of missing values (solid line: nnsRP,
dashed line: nsRP, dotted line: RT).
Table 3 Differences between EORTC QLQ-C30 ProCaSP data a
Baseline
Radical prostatectomy Radiotherapy
nns ns total brachy comb
Global quality of life 2.5 5.3 1.5 4.6 −1.7
Functioning scales
Physical 7.3 9.6 3.0 3.5 2.3
Role 9.7 14.0 3.6 11.0 2.3
Emotional −8.7 −9.3 −3.8 −2.8 −13.2
Cognitive 1.4 2.1 1.7 3.9 −1.5
Social −3.1 −2.9 −4.9 −6.4 −13.1
Symptom scales
Fatigue −10.0 −13.5 −6.9 −9.9 −0.4
Nausea/Vomiting −1.1 −1.7 0.4 1.8 1.9
Pain −12.9 −19.0 −8.7 −8.3 −7.0
Single items
Dyspnoea −9.3 −9.0 −4.9 −9.6 −1.1
Insomnia −2.8 −4.8 −1.2 −4.9 10.7
Appetite loss −2.5 −2.0 −1.6 −3.5 0.6
Constipation 2.8 0.3 1.7 3.5 2.6
Diarrhoea 0.5 −2.1 3.6 1.7 8.4
Financial difficulties −6.7 −8.4 −3.1 −4.3 4.5
Legend: positive differences = higher mean functioning or higher mean symptom s
differences = lower mean functioning or higher mean symptom score in the prostat
Bold numbers indicate clinical relevance.
nns = non-nerve-sparing, ns = nerve-sparing, brachy = brachytherapy, extern = extern
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instruments are not able to a) distinguish adequately be-
tween highly selected groups [26] and b) adequately
measure HRQOL after diagnosis because of response
shift bias [36,37]. In this analysis, the application of mul-
tiple imputation may have obscured differences; the in-
corporation of uncertainty due to missing values often
results in conservative estimates.
A clinically relevant worsening in PORPUS-P and an
increase in emotional functioning at all measurement
time points after baseline were observed in the RP group
(with exceptions for emotional functioning in the nnsRP
group). Differences between RP patients and norm
values were close to clinical relevance at baseline (−8.7
and −9.3, respectively) [29]. At the end of the follow-up
differences in emotional functioning had largely disap-
peared, which may be ascribed to adaptation processes
[38]. Our findings are in contrast to those of a Canadian
study observing clinically relevant decreases of prostate-
specific HRQOL after radiotherapy [39]. This is particu-
larly interesting as over 50% of our RT patients, where
information about pre-baseline androgen deprivation
therapy was available, received ADT, i.e. an adjuvantnd norm data
24 months after baseline
Radical prostatectomy Radiotherapy
extern nns ns total brachy comb extern
1.3 5.3 10.3 2.0 3.8 2.8 0.1
3.2 5.0 8.5 0.0 1.6 −1.3 −0.5
12.2 9.7 14.1 4.6 −0.5 5.9 9.6
1.5 −1.6 4.4 −0.4 2.1 −2.7 −1.6
2.1 −2.4 2.0 −1.6 0.8 −6.5 −0.2
2.4 −5.2 −1.8 −2.2 −7.5 1.9 1.5
−9.3 −4.5 −9.8 −3.4 −3.5 −1.5 −4.6
−1.6 −0.8 −1.7 −0.6 0.8 −1.3 −1.6
−10.5 −9.6 −14.0 −6.8 −5.4 −10.8 −9.4
−3.3 −8.1 −4.9 −2.7 −6.5 −0.5 0.7
−6.6 0.1 −4.5 0.0 −4.0 10.6 −1.1
−1.3 −2.8 −4.3 −0.5 −2.6 −3.8 3.5
−0.4 1.9 −1.3 2.8 5.4 0.0 3.6
2.1 0.4 −0.9 5.8 7.7 0.4 6.5
−7.4 −2.8 −6.1 −2.3 0.0 −4.5 −2.3
core in the prostate cancer patient group than in the norm data, negative
e cancer patient group than in the norm data.
radiotherapy, comb = extern radiotherapy and brachytherapy.
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cial functioning, and global health/HRQOL [39]. Hence,
a clinically relevant decrease of HRQOL scores in our RT
patients would have been expected. In a joint analysis of
the Canadian data and our data, however, we were able to
show that RT patients with ADT indeed scored lower
HRQOL than RT patients without ADT [40].
Treatment effects
When controlling for baseline HRQOL, sexual function-
ing, and other possible confounders in a GEE model,
the treatment effect of nsRP compared to nnsRP was
favourable for many HRQOL domains and often un-
favourable for RT. The treatment effect was significant
for the domain diarrhoea of the HRQOL and for the
PORPUS-P. The negative effect of RT on bowel func-
tioning is in agreement with previous research [41,42].
However, treatment effects in our analysis never reached
clinical relevance.
The treatment groups differed with respect to their
baseline HRQOL, sexual functioning, and sociodemo-
graphic and tumour-related characteristics. Baseline
HRQOL and sexual functioning was generally highest in
patients receiving nsRP and lowest in patients receiving
RT, especially in the combRT group. RT patients were
older than RP patients, and the combRT group had the
highest risk profile. Similar results have been reported in
comparable international outcome studies [12,41] which
is concordant with recommendations in current therapy
guidelines such as the EAU-guideline advising an esti-
mated 10-year survival as a precondition for RP but not
for RT [43]. Logistic regression indicated that the signifi-
cant predictors for a successful nerve-sparing surgery (in
contrast to a non-nerve-sparing surgery) were a younger
age, a higher Gleason score, and a better sexual func-
tioning of the patient, while predictors for choosing
radiotherapy were a better T-category, a worse sexual
functioning, and an urban living area. However, there
was considerable overlap with regard to these variables
between the treatment groups, and the covariate adjust-
ment in the regression analyses allowed to derive meaning-
ful treatment effect estimates despite the group differences.
Comparison to reference population
Patients treated with RP had clinically relevant lower
scores of fatigue and pain and higher role functioning
than age-matched German men of the general popula-
tion. The RT group also had lower fatigue and pain
scores than suggested by the reference data but the
difference was not clinically relevant (except for the
externRT subgroup at baseline and the combRT sub-
group after 24 months for pain). It can be suspected that
the high proportion of participants reporting depression
in the reference population caused artificially high normvalues for fatigue and pain and low values for role func-
tioning [29]. Even the ‘low’ symptom values (pain, fa-
tigue) of the cancer patients in our study were higher
than those reported by Krahn et al. (2009) for Canadian
early stage prostate cancer patients [39]. The same ap-
plies to the role functioning values in the RP group.Strengths and limitations
Important strengths of the ProCaSP Study are the multi-
center design, the comparison of HRQOL outcomes in
several prostate cancer treatment groups, and the appli-
cation of suitable statistical methods such as GEEs and
adjustments for baseline differences. The main limitation
of the study is missing data due to drop-out or incomplete
questionnaires, especially for IIEF questions; however, by
applying multiple imputation methods we achieved a sam-
ple size sufficient for stratification of two RP and three RT
groups. The exclusion of urinary measures because of in-
sufficient psychometric properties of the Prostate Specific
Module limits the scope of our study. Finally, selection bias
caused by an overrepresentation of severe cases in univer-
sity hospitals cannot be ruled out. Possible confounding
was handled by adjustment of covariates in the GEE model,
although residual confounding cannot be excluded.Conclusions
Our results support the findings from previous research.
A fundamental basis of both empirical research and
evidence-based medicine is the reproducibility of findings
in different settings, health care systems, and different co-
horts of patients. In conclusion, RT cancer patients scored
lowest on HRQOL at baseline and throughout the study.
RP had a larger negative impact on sexual functioning than
RT. In patients with similar baseline characteristics and
similar baseline HRQOL, treatment by RT increased symp-
toms of diarrhoea, and nnsRP decreased prostate-specific
HRQOL. In view of the relevant proportion of overdiagno-
sis in prostate cancer and in view of improved survival rates
for prostate cancer patients, physicians should inform their
patients about these differences in HRQOL outcomes and
take them into account when deciding which therapy is
best for an individual patient.Additional files
Additional file 1: Sexual functioning Radiotherapy Subgroups.tiff.
Sexual functioning in the radiotherapy subgroups. Mean scores of
brachytherapy, external radiotherapy, and combined radiotherapy cancer
patients at baseline and during the 24-month follow-up period after
multiple imputation of missing values (circle: brachyRT, triangle: externRT,
cross: combRT).
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quality of life in the radiotherapy subgroups. Mean scores of brachytherapy,
external radiotherapy, and combined radiotherapy cancer patients at baseline
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of missing values (circle: brachyRT, triangle: externRT, cross: combRT).
Additional file 3: PorpusP Radiotherapy Subgroups.tiff. PORPUS-P
in the radiotherapy subgroups. Mean scores of brachytherapy, external
radiotherapy, and combined radiotherapy cancer patients at baseline
and during the 24-month follow-up period after multiple imputation
of missing values (circle: brachyRT, triangle: externRT, cross: combRT).
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